tiprankstipranks
Blurbs

Analysts Offer Insights on Healthcare Companies: Alnylam Pharma (ALNY), Baxter International (BAX) and Merck & Company (MRK)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Alnylam Pharma (ALNYResearch Report), Baxter International (BAXResearch Report) and Merck & Company (MRKResearch Report).

Alnylam Pharma (ALNY)

In a report released today, Matthew Harrison from Morgan Stanley maintained a Hold rating on Alnylam Pharma, with a price target of $170.00. The company’s shares closed last Friday at $137.28, close to its 52-week low of $125.00.

According to TipRanks.com, Harrison is a 5-star analyst with an average return of 8.9% and a 52.7% success rate. Harrison covers the Healthcare sector, focusing on stocks such as Global Blood Therapeutics, Centessa Pharmaceuticals, and BioMarin Pharmaceutical.

Currently, the analyst consensus on Alnylam Pharma is a Moderate Buy with an average price target of $200.36, which is a 41.1% upside from current levels. In a report released today, Leerink Partners also maintained a Hold rating on the stock with a $96.00 price target.

See today’s best-performing stocks on TipRanks >>

Baxter International (BAX)

Morgan Stanley analyst Drew Ranieri maintained a Buy rating on Baxter International today and set a price target of $100.00. The company’s shares closed last Friday at $71.67, close to its 52-week low of $69.88.

According to TipRanks.com, Ranieri is a 1-star analyst with an average return of -5.3% and a 37.8% success rate. Ranieri covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Zimmer Biomet Holdings, and Intuitive Surgical.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Baxter International with a $92.50 average price target, which is a 31.7% upside from current levels. In a report released today, Raymond James also maintained a Buy rating on the stock with a $85.00 price target.

Merck & Company (MRK)

Morgan Stanley analyst Terence Flynn maintained a Hold rating on Merck & Company today and set a price target of $87.00. The company’s shares closed last Friday at $88.46, close to its 52-week high of $91.40.

According to TipRanks.com, Flynn is a 4-star analyst with an average return of 13.7% and a 63.9% success rate. Flynn covers the Healthcare sector, focusing on stocks such as Arvinas Holding Company, Johnson & Johnson, and Eli Lilly & Co.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Merck & Company with a $95.82 average price target, which is an 8.1% upside from current levels. In a report issued on April 25, Berenberg Bank also maintained a Hold rating on the stock with a $87.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on ALNY:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
---

Latest News Feed